The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Christopher D. Adams.

## DIGEST 2015 Regular Session

Mills

<u>Proposed law</u> changes the name of the Louisiana Board of Wholesale Drug Distributors to the Louisiana Board of Drug and Device Distributors.

<u>Proposed law</u> changes the name of the Louisiana Wholesale Drug Distributors Act to the Louisiana Drug and Device Distributors Act.

<u>Proposed law</u> changes "wholesale drug distribution business" to "legend drug or legend device distribution business".

<u>Proposed law</u> redefines "applicant" to mean a person who applies for licensure as a legend drug or legend device distributor.

<u>Proposed law</u> defines "designated responsible party" to mean a natural person designated by the applicant or licensee as responsible for facility operations of the applicant or licensee facility.

<u>Proposed law</u> defines "distribution" to mean the sale or facilitation of delivery of legend drugs or legend devices to other than the consumer or patient, including but not limited to distribution by manufacturers, repackagers, own label distributors, jobbers, third-party logistics providers, retail pharmacy warehouses, pharmacies, brokers, agents, and wholesale distributors.

<u>Proposed law</u> defines "distributor" to mean any person engaged in distribution, including but not limited to manufacturers, repackagers, own label distributors, jobbers, third-party logistics providers, retail pharmacy warehouses, pharmacies, brokers, agents, and wholesale distributors.

<u>Proposed law</u> repeals the definition of "legend drug pedigree".

SB 39 Engrossed

Proposed law amends the definition of "licensure" to include permit or registration.

Proposed law amends the definition of "manufacturer" to mean any of the following:

- (1) A person who manufactures legend drugs or legend devices and includes a labeler or primary distributor.
- (2) A person who prepares legend drugs in dosage form by mixing, compounding, encapsulating, entableting, or by other processes.
- (3) A person who manufactures, assembles, processes, or modifies legend devices.

- (4) An affiliate of a person described in <u>proposed law</u> that receives the legend drugs or legend devices directly from a person described in <u>proposed law</u>.
- (5) A co-licensed partner of the person described in <u>proposed law</u> that obtains the legend drugs or legend devices directly from a person described in <u>proposed law</u>.

Proposed law repeals the definition of "responsible party".

<u>Proposed law</u> defines "repackager" to mean a person who owns or operates an establishment that repacks and relabels a legend drug, legend device, or package thereof for one of the following:

- (1) Further sale.
- (2) Distribution without a further transaction.

<u>Proposed law</u> amends the definition of "third-party logistics provider" to mean a person that provides or coordinates warehousing, facilitation of delivery, or other logistic services for a legend drug or legend device in interstate and intrastate commerce on behalf of a manufacturer, distributor, or dispenser of a legend drug or legend device but does not take ownership of the legend drug or legend device nor have responsibility to direct the sale or disposition of the legend drug or legend device.

<u>Proposed law</u> defines "transaction" to mean the transfer of a legend drug between persons in which a change of ownership occurs.

<u>Proposed law</u> defines "transaction history" to mean a statement, in paper or electronic form, including the transaction information for each prior transaction going back to the manufacturer of the legend drug.

Proposed law defines "transaction information" to mean:

- (1) The proprietary or established name or names of the legend drug.
- (2) The strength and dosage form of the legend drug.
- (3) The National Drug Code number of the legend drug.
- (4) The container size.
- (5) The number of containers.
- (6) The lot number of the legend drug.
- (7) The date of the transaction.
- (8) The date of the shipment, if more than twenty-four hours after the date of the transaction.

- (9) The business name and address of the person from whom ownership is being transferred.
- (10) The business name and address of the person to whom ownership is being transferred.

<u>Proposed law</u> defines "transaction statement" to mean a statement, in paper or electronic form, that the entity transferring ownership in a transaction:

- (1) Is authorized as required under the Drug Supply Chain Security Act and as required by the board.
- (2) Received the legend drug or legend device from a person that is authorized as required under the Drug Supply Chain Security Act and as required by the board.
- (3) Received transaction information and a transaction statement from the prior owner of the legend drug.
- (4) Did not knowingly ship a suspect or illegitimate legend drug.
- (5) Had systems and processes in place to comply with verification requirements under the Drug Supply Chain Security Act and as required by the board.
- (6) Did not knowingly provide false transaction information.
- (7) Did not knowingly provide false transaction history.

<u>Proposed law</u> defines "wholesale distribution" to mean the sale or facilitation of delivery of legend drugs or legend devices to other than the consumer or patient, but does not include sale or distribution of legend drugs or legend devices by manufacturers, manufacturers' co-licensed partners, repackagers, or third-party logistics providers.

<u>Proposed law</u> defines "wholesale distributor" to mean any person engaged in wholesale distribution, but does not include manufacturers, manufacturers' co-licensed partners, or third-party logistics providers.

<u>Proposed law</u> amends the qualifications of board members to require each one to be at least 21 years of age, of good moral character and temperate habits, and a resident of Louisiana and shall have engaged in distribution as defined by law.

<u>Proposed law</u> amends the duties and powers of board to not only approve, deny, revoke, or suspend licenses but to also limit or restrict a license. The board is also granted the authority to impose a fine, assess cost, or otherwise discipline a licensee and to require a licensee to provide transaction history, transaction information, and a transaction statement. The board shall make rules and regulations to comply with the requirements of the Federal Drug Supply Chain Security Act pertaining to distribution as defined by law.

<u>Proposed law</u> requires the board to require all distributors and wholesale distributors to furnish a bond or other equivalent means of security.

<u>Proposed law</u> amends requirements for licensure to be all qualifications and requirements designated by the board as required by law.

Proposed law changes "responsible party" to "designated responsible party".

Proposed law makes changes for inspections from "facilities" to "distribution and sales facilities".

Proposed law changes "wholesale drug distributor" to "distributor".

Proposed law changes for reinspections from "facilities" to "distribution and sales facilities".

<u>Proposed law</u> changes for applicants from other states from "wholesale drug distributors" to "distributors of the same type".

<u>Proposed law</u> includes limitation or revocation of license as a discipline option by the board against a licensee.

<u>Proposed law</u> provides the refusing to permit entry to the licensed distribution or sales facility to comply with any inspection during normal business hours as a cause for discipline.

<u>Proposed law provides that any disciplinary actions or the denial, revocation, suspension, limitation, or restriction of a license shall be conducted in accordance with rules and regulations adopted pursuant to the Administrative Procedure Act.</u>

<u>Proposed law</u> changes "wholesale drug distribution" to "distribution" regarding enforcement actions against other persons.

<u>Proposed law</u> changes "wholesale drug distributor" to "distributor or wholesale distributor" regarding enforcement actions against other persons.

<u>Proposed law</u> changes "wholesale drug distribution" to "distribution" regarding injunction proceedings.

<u>Proposed law</u> changes "wholesale drug distributor" to "distributor" regarding an order to quarantine a legend drug or a legend device.

<u>Proposed law</u> changes "wholesale drug distributors" to "distributors" regarding an annual renewal of license.

<u>Proposed law</u> changes "responsible party" to "designated responsible party" regarding consent to the board for the board to obtain criminal history record information.

<u>Proposed law</u> changes "wholesale drug distribution" to "distribution" regarding unlawful participation and changes "wholesale drug distributor" to "distributor" regarding the same.

<u>Proposed law</u> changes "wholesale drug distributors" to "distributors" regarding unauthorized sales and mandatory reporting.

<u>Proposed law</u> changes the requirement that distributors provide copies of the United States Enforcement Accounting Records Controlled Order Substance Reports of the preceding month to the Louisiana Board of Pharmacy by the fifteenth day of each month. <u>Proposed law</u> requires the reporting but removes the preceding month language and the fifteenth day of each month language.

<u>Proposed law</u> repeals the provisions related to manufacturer distribution of legend drugs and legend devices.

Effective upon signature of the governor or lapse of time for gubernatorial action.

(Amends R.S. 37:3461, 3462, 3463(A), 3464, 3467, 3469, 3470, 3471(A), 3472, 3473, 3474.1(A)(1), (2), and (5) and (B), 3474.2(A)(1) and (2), 3474.3(A), 3474.4, 3475, 3477(A), (D), and (E), 3478(A) and (B), 3480, 3481, and 3482; repeals R.S. 37:3474)

## Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Defines "applicant" to mean a person who applies for licensure as a legend drug or legend device distributor.